Estamos realizando la búsqueda. Por favor, espere...
1582
37
170
29108
4409
2600
347
389
Abstract: A high priority problem in multiple myeloma (MM) management is the development of resistance to administered therapies, with most myeloma patients facing successively shorter periods of response and relapse. Herewith, we review the current knowledge on the mechanisms of resistance to the standard backbones in MM treatment: proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies (mAbs). In some cases, strategies to overcome resistance have been discerned, and an effort should be made to evaluate whether resensitization to these agents is feasible in the clinical setting. Additionally, at a time in which we are moving towards precision medicine in MM, it is equally important to identify reliable and accurate biomarkers of sensitivity/refractoriness to these main therapeutic agents with the goal of having more efficacious treatments and, if possible, prevent the development of relapse.
Fuente: Cells , 2019, 8(11), 1432
Editorial: MDPI
Año de publicación: 2019
Nº de páginas: 18
Tipo de publicación: Artículo de Revista
DOI: 10.3390/cells8111432
ISSN: 2073-4409
Url de la publicación: https://doi.org/10.3390/cells8111432
Consultar en UCrea Leer publicación
MOGOLLÓN, PEDRO
DÍAZ TEJEDOR, ANDREA
ALGARÍN, ESPERANZA M.
PAÍNO, TERESA
GARAYOA, MERCEDES
ENRIQUE MARIA OCIO SAN MIGUEL
Volver